Elanco Animal Health (NYSE:ELAN) Reaches New 1-Year High - Should You Buy?

Key Points

• Elanco Animal Health shares hit a new 52-week high of $19.37, marking a notable increase from the previous close of $18.92, with a trading volume of nearly 1 million shares.
• Recent analyst upgrades include a rise from "market perform" to "outperform" by William Blair, and a price target increase from $18.00 to $19.00 from UBS Group.
• The company reported $0.26 EPS for Q2, exceeding estimates, and a revenue of $1.24 billion, up 4.8% year-over-year.

Shares of Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) reached a new 52-week high on Friday . The company traded as high as $19.36 and last traded at $19.37, with a volume of 988477 shares changing hands. The stock had previously closed at $18.92.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ELAN shares. William Blair upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday, June 26th. Leerink Partnrs upgraded shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 17th. UBS Group raised their price objective on shares of Elanco Animal Health from $18.00 to $19.00 and gave the company a "buy" rating in a research report on Friday, August 8th. Leerink Partners raised Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 target price on the stock in a research note on Thursday, July 17th. Finally, Zacks Research cut shares of Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $18.33.

Elanco Animal Health Stock Up 3.4%

The company has a market capitalization of $9.72 billion, a P/E ratio of 22.75, a price-to-earnings-growth ratio of 3.48 and a beta of 1.62. The company has a current ratio of 2.60, a quick ratio of 1.40 and a debt-to-equity ratio of 0.61. The stock's fifty day moving average is $17.09 and its 200 day moving average is $13.67.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.20 by $0.06. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.19 billion. During the same period in the prior year, the firm posted $0.30 earnings per share. The company's quarterly revenue was up 4.8% compared to the same quarter last year. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Research analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Hedge Funds Weigh In On Elanco Animal Health

Several hedge funds and other institutional investors have recently modified their holdings of ELAN. Allworth Financial LP grew its holdings in shares of Elanco Animal Health by 791.7% in the first quarter. Allworth Financial LP now owns 2,354 shares of the company's stock worth $25,000 after acquiring an additional 2,090 shares during the period. First Horizon Advisors Inc. increased its position in Elanco Animal Health by 184.3% in the second quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company's stock worth $53,000 after buying an additional 2,414 shares in the last quarter. Parallel Advisors LLC raised its stake in shares of Elanco Animal Health by 92.2% in the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock worth $41,000 after buying an additional 1,852 shares during the period. NBC Securities Inc. bought a new position in shares of Elanco Animal Health in the first quarter worth about $40,000. Finally, Caitong International Asset Management Co. Ltd lifted its position in shares of Elanco Animal Health by 261.6% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 4,039 shares of the company's stock valued at $58,000 after buying an additional 2,922 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.